INTRODUCTION {#S1}
============

Werner syndrome (WS) is an autosomal recessive disease that first captured wide attention due to its prominent premature aging (or progeroid) features. WS is also of considerable biomedical science interest in light of the pairing of these progeroid features with constitutional genomic instability and an elevated risk of many clinically important, age-dependent human diseases.

The progeroid features of WS were first well-described by Otto Werner ([@R86]), who described a North German family of four siblings, ages 31 -- 40, with short stature, prematurely gray hair, bilateral cataracts, atrophy of the extremities, hyperkeratosis and scleroderma-like changes together with foot and ankle skin ulceration. He noted one of the siblings, a 36 yr old male, gave "...the impression of extreme senility." These observations were published as part of Werner's doctoral thesis prior to his embarking on a career in a small North Sea village. Werner never again returned to study his syndrome ([@R56]).

The term 'Werner's syndrome' was first used in a subsequent report of an additional patient who resembled the family members seen by Werner ([@R53]). This case report together with a more comprehensive study by Thannhauser of five additional patients ([@R73]) provided a detailed description of WS. Werner syndrome was next 'rediscovered' by colleagues at the University of Washington who described three Japanese-American sisters with WS (one of whom is shown in [Figure 1](#F1){ref-type="fig"}). Their analysis established the autosomal recessive inheritance of WS and delineated key differences between WS and normal aging ([@R20]).

Werner syndrome as a clinical entity {#S2}
====================================

The most consistent and earliest noted findings are premature graying and loss of hair together with bilateral cataracts, short stature and progressive, scleroderma-like skin changes ([Table 1](#T1){ref-type="table"})([@R20]; [@R27]; [@R77]). Hair graying and loss begin in the second decade with the scalp and eyebrows, as do bilateral ocular cataracts. The short stature of WS patients reflects the absence of a pubertal growth spurt. Short stature together with progressive limb thinning, atrophy and a stocky trunk give many patients a 'cushingoid' appearance (see Figure 2 of ([@R28])).

The scleroderma-like skin changes of WS ([@R73]) consist of a mix of atrophic and proliferative changes: epidermal atrophy that includes skin appendages in conjunction with focal hyperkeratosis and basal hypermelanosis. Dermal subcutaneous atrophy is often found with dermal fibrosis underlying atrophic skin ([@R20]; [@R27]; [@R32]; [@R73]). These changes give skin a 'tight, white and shiny' appearance, with a progressive sharpening of facial features to give a 'pinched', 'beaked' or 'bird-like' appearance (see Figure 3 in ([@R28])). The lower extremities, especially the feet, may be markedly deformed with ulceration and calcification of soft tissue and tendons ([@R32]).

Many of these changes are readily apparent in patient photos taken in early adulthood and later in life ([Figure 1](#F1){ref-type="fig"}). The progressive development of phenotype makes the diagnosis of WS challenging, especially in young adults. However cardinal features are often present early, and can be used together with molecular confirmation to confirm or exclude a diagnosis ([Table 1](#T1){ref-type="table"})([@R34]).

Related RECQ helicase deficiency syndromes {#S3}
==========================================

The positional cloning of the *WRN* locus ([@R92]) and other members of the *RECQ* helicase gene family led to recognition of deeper links between WS and two additional genodermatoses: Bloom syndrome (BS)([@R19]) and Rothmund-Thomson syndrome (RTS)([@R39]). Bloom syndrome patients display congenital short stature and a characteristic sun-sensitive 'butterfly' rash across the bridge of the nose and cheeks that may involve hands and forearms ([@R6]). Many patients display cellular and humoral immune deficits; an elevated risk of otitis media, pneumonia and diabetes mellitus with reduced fertility. Cancer is the leading cause of premature death ([@R6]; [@R22], [@R23], [@R24]).

Rothmund-Thomson syndrome (RTS) was first described as a familial occurrence of skin changes with bilateral juvenile cataracts ([@R58]; [@R71]; [@R74]). A characteristic sun-sensitive rash with redness, swelling and blistering appears in the first year of life, and may involve the buttocks and extremities while sparing the chest, back and abdomen. The rash may further develop variable pigmentation, telangiectasia and focal atrophy. Hair, eyelashes and eyebrows are often sparse or absent. Congenital short stature is common, though less severe than in BS. Developmental abnormalities include dysplastic, malformed or absent bones, often in the hand or thumbs; delayed bone formation or bone density loss; and malformed, missing or extra teeth. Cataracts have been documented in only a minority of contemporary RTS patients ([@R42]; [@R83]). Cancer risk is largely limited to osteosarcoma ([@R69]; [@R82]). Immunologic function appears intact, but fertility may be reduced. Additional diseases associated with *RECQL4* mutations are RAPADILINO and Baller-Gerold (BGS) syndromes. RAPADILINO syndrome patients have joint dislocations and patellar hypoplasia or aplasia, but lack skin changes. BGS patients have craniosynostosis with radial aplasia, and RTS-like skin changes ([@R68]; [@R69]; [@R78]). Life expectancy appears normal in the absence of cancer ([@R42]; [@R83]).

Elevated acquired disease risk in Werner syndrome {#S4}
=================================================

Many WS patients prematurely develop age-dependent diseases such as myocardial infarction and stroke; cancer; osteoporosis; diabetes mellitus; and hypogonadism. Cardio-vascular disease and cancer are leading causes of premature death ([@R27]; [@R29]). The elevated risk of neoplasia is quite selective: two-thirds of neoplasms in WS patients were of 6, not obviously related, tumor types: thyroid epithelial carcinomas, melanomas, meningiomas, soft tissue sarcomas, hematologic neoplasia, chiefly leukemias, and osteosarcoma ([@R43]; [@R44]; [@R50]). Multiple neoplasms were common: 22% of 189 patients in our series had 1 to 4 concurrent or sequential neoplasms, often of unusual types or at unusual sites. For example, melanomas were almost exclusively less common variants: acral lentiginous melanomas arising on the palms, soles or in nail beds; and mucosal melanomas arising in the nasal cavity or esophagus. Thyroid neoplasms, in similar fashion, were disproportionately less common follicular carcinomas ([@R43]). The excess risk of these specific neoplasms, estimated using a combination of standardized incidence ratio (SIR), proportional incidence ratio (SPIR) analyses, ranged from nearly 60-fold for melanoma to 1.5-fold for leukemia and pre-leukemic disorders ([@R43]). This spectrum of neoplasia overlaps with, but is distinct from, the neoplasms observed in BS and RTS ([@R24]; [@R51]; [@R69]). BS is unusual among heritable cancer predispositions as *many* different tumor types are involved ([@R24]; [@R51]). The cancer risk in the RTS-associated *RECQL4* syndromes is, conversely, restricted largely to osteosarcoma and lymphoma ([@R69]; [@R82]; [@R83]).

Physiologic roles of RECQ helicases {#S5}
===================================

All of the human RECQ helicases hydrolyze ATP, unwind double-stranded DNA and possess good DNA strand annealing activity. WRN alone possesses an additional, 3\' to 5\' exonuclease activity. Despite their common biochemical activities, the three disease-associated RECQ helicases have differing substrate preferences and different sets of protein partners (reviewed in ([@R3]; [@R7]; [@R14]; [@R67])). These biochemical data together with functional and cellular data begin to indicate how these seemingly similar proteins fill different physiologic 'niches' in human cells and, by extension, how the loss of function of one RECQ protein may lead to distinct cellular and organismal phenotypes.

Functional characterizations have identified distinct roles in specific RECQ helicase proteins in DNA replication. For example, RECQL4 and to a lesser extent RECQL bind replication origins and contribute to DNA replication initiation ([@R72]; [@R89]). Single molecule DNA replication track analyses we and others have performed revealed roles for BLM, WRN and RECQL in replication fork rate maintenance and fork restart ([@R5]; [@R65]; [@R66]). RECQL4 has an interesting additional role in mtDNA maintenance: it is co-imported with TP53, and appears to limit mtDNA damage in a replication-dependent manner ([@R15]; [@R16]; [@R31]).

Several RECQ helicases also help maintain telomeres, though again display apparent functional specialization. Telomeric DNA poses a dual challenge to the DNA replication machinery as it is composed of repeated (the human telomeric repeat sequence is TTAGGG), GC-rich DNA organized into a unique chromatin 'cap' at the ends of chromosomes ([@R61]). G-rich lagging strands may form G4 DNA quadruplex structures ([@R46]) which are a good biochemical substrates for WRN and BLM. Only WRN helicase activity is required for complete replication of telomeric G-rich lagging strands, whereas cells lacking RECQL, RECQL4 or BLM also show telomere breakage and loss. It is unclear whether these effects are via a common mechanism ([@R4]; [@R12]; [@R13]; [@R25]; [@R57]). In contrast, WRN and BLM both participate in the recombination-mediated 'alternative lengthening of telomeres' (ALT) pathway used by many tumor cells to gain replicative immortality ([@R49]). One phenomenon that is not yet well-understood is the sensitivity of WRN+ cells to telomere-homologous DNA oligonucleotides ('T-oligos'). The ability to respond to T-oligos may depend upon WRN exonuclease activity, and may have therapeutic potential in light of protective or deleterious responses in different cell types ([@R18]; [@R26]).

All five of the human RECQ helicases also participate in DNA double strand break repair by non-homologous DNA end joining (NHEJ) or homology-dependent recombination (HDR or HR). WRN and RECQL4 participate in base excision repair, and RECQL5 may play an additional role in ssDNA break repair (reviewed in ([@R7]; [@R14]; [@R67]).

'Rewritten in the skin' -- RECQ helicases in transcription {#S6}
==========================================================

Previous analyses had suggested a role for the WRN and BLM RECQ helicases in transcription ([@R35]; [@R40]). In order to better understand this role, we analyzed gene and miRNA expression in mutation-typed WS and BS primary fibroblasts and in isogenic control primary fibroblasts depleted of the WRN or BLM protein. These analyses identified −3,000 genes and dozens of miRNAs whose expression was significantly altered by the loss of WRN and BLM function. Among the subset (−25%) of genes altered in both WS and BS cells, a surprisingly high fraction (\>90%) had expression altered in the same direction ([@R52])(Tang, Robles et. al., in preparation). Many WRN- and BLM-responsive downregulated genes contained G quadruplex (G4) DNA motifs in their 5\' ends, providing strong evidence that G4 DNA structures are physiologic as well as biochemical substrates for WRN and BLM.

The genes and miRNAs altered in WS and/or BS cells play important roles in pathways that drive cell growth, proliferation, death and survival. BS patient cells had gene expression patterns predicted to alter DNA replication recombination and repair, as well as immune function and tumorigenic/DNA damage signaling. These make good sense in light of our understanding of the biochemical, cellular and organismal phenotype of BS ([@R52])(Tang, Robles et. al., in preparation). WS appears more complex, and thus intriguing. One remarkable---and as yet not fully understood---finding in WS cells was coordinate upregulation of nearly all of the cytoplasmic tRNA synthestase (ARS) and synthetase-associated interacting protein (AIMP) genes ([@R38]; [@R54]; [@R81]; [@R90]).

The mechanism of ARS/AIMP upregulation is not yet understood but may include MYC, which can alter and in turn be modulated by ARSs ([@R63]) while driving expression of *WRN* and telomerase ([@R30]). ARS and AIMP overexpression in WS could perturb protein homeostasis by altering global protein turnover and/or translational fidelity ([@R45]; [@R87]). Altered tRNA charging could affect the balance between mitochondrial and nuclear protein synthesis to promote mitochondrial dysfunction and oxidative stress ([@R36]). It could also drive disease pathogenesis via the growing list of ARS/AIMP 'non-canonical' functions that modulate disease-related metabolic, developmental, angiogenic, tumorigenic, immune and inflammatory pathways ([@R55]; [@R70]). All of these areas are ripe for further exploration using a combination of new genomic and proteomic approaches.

The origins of phenotype {#S7}
========================

The biochemical and cellular specializations of the individual RECQ helicases outlined above begin to indicate how the loss of function of a single RECQ protein may lead to specific RECQ deficiency syndromes and their associated disease risks. As noted above, RECQ-deficient cells display cell proliferation defects in conjunction with genomic instability ([@R17]; [@R47]; [@R48]; [@R62]; [@R65]; [@R72]; [@R84]). These cellular defects in turn are likely part of the explanation for why BS and RTS patients are often small though proportionately developed. BLM or RECQL4 loss can both interfere with DNA replication and impair cell production throughout development. Despite this, development appears largely normal in both syndromes and responds by proportionately scaling output (the fetus) to reflect inadequate substrate (cells). This proportional dwarfing is particularly striking in BS, where patients are born and often remain at or below the 5th percentile for height and weight ([@R37]).

The progressive development of progeroid features in WS only after development is largely complete may reflect the starkly different outcome of replication arrest, which leads to high levels of cell death in BS though not in WS cells ([@R47]; [@R65]). WRN loss, in contrast, has a more profound effect on transcription than does BLM loss, and thus may have a correspondingly more prominent role in transcription and tissue maintenance (see above). Disrupted DNA metabolism in WS patient cells could drive the progressive accumulation of mutant and senescent cells in many tissues, with acquisition of a senescence-associated secretory phenotype that could in turn promote the elevated risk of many clinically important age-associated diseases ([@R8]). Cellular senescence in the RECQ helicase syndromes may have one modest silver lining: it is an effective, albeit non-specific, tumor-suppressive mechanism ([@R1]; [@R11]). Altered *RECQ* expression, as opposed to mutation, may be frequent in many tumor types ([@R41]). However the previous suggestion that these changes may be largely methylation-driven ([@R2]) has not been consistent enough in our hands to serve as a reliable marker for altered *WRN* expression in tumors ([@R41])(Bosch, Luo *et al*, in preparation).

More systematic collection of patient data, longitudinal study of patients, and the collection and distribution of well-characterized clinical samples should all aid our understanding of the RECQ deficiency syndromes. We also have a growing range of options to capture and analyze patient-derived cells and cell lines, including improved short term primary culture, organoid culture and the generation of cell lines and iPS cells ([@R9]; [@R48]; [@R64]; [@R88]). These analyses and materials have the potential to identify genetic and environmental modifiers of disease progression and acquired disease risk.

New clues to skin biology, disease and therapy {#S8}
==============================================

The above analyses emphasize the complexity of disease pathogenesis in even 'simple' monogenic genetic diseases such as Werner syndrome. They also emphasize how new insights into disease pathogenesis from rare heritable diseases may improve our understanding of skin biology while identifying potential new therapies. One example comes from another skin disease, recessive dystrophic epidemolysis bullosa (RDEB). RDEB results from *COL7A1* mutations leading to loss of Type VII collagen, a marked reduction in anchoring fibrils and extreme skin fragility with loss and scaring ([@R76]).

The potential for genetic therapies of EB and a handful of other heritable diseases was emphasized over two decades ago by the identification of patients who had undergone spontaneous reversion of causative mutations with partial or full correction of disease-specific defects in skin, blood, lymphoid or liver ([@R33]). A deeper understanding of the role of Type VII collagen in skin ([@R76]) had led to a diversity of therapeutic approaches: complementation ([@R21]) or targeted correction of causative *COL7A1* mutations in epidermal cells ([@R59]); use of patient-derived, mutation-reverted keratinocytes ([@R75]); and the repair *in trans* of anchoring fibrils using allogeneic fibroblasts ([@R79]), mutation-corrected, iPS-derived fibroblasts ([@R85]) or bone marrow transplantation ([@R76]; [@R80]). Repair *in trans* may be a viable option for dealing with the scleroderma-like skin changes seen in WS, as might aminoglycoside suppression of *WRN* missense mutations, a strategy that has been used in RDEB ([@R10]).

Another unusual example of where we may find new clues to treating heritable or acquired skin disease as well as age-associated changes comes from comparative genetics, more specifically the African spiny mice *Acomys kempi* and *Acomys percivali. Acomys* mice have the remarkable ability to shed--and then regenerate without scaring--large segments of skin, and may have evolved this ability to escape predators ([@R60]). While scarless wound healing also occurs in humans, it is largely restricted to the fetus ([@R91]). *Acomys* mice, in contrast, are able to continuously regenerate skin without scaring in the face of injury, inflammation and infection. Understanding the mechanistic basis for this remarkable example of epimorphic regeneration may identify new ways to maintain or rejuvenate skin, and to help individuals with injuries that lead to disfiguring scaring. Nature undoubtedly holds more examples of remarkable cutaneous biology. Finding these and turning them to good use will require imagination, together with a willingness to look---and think---a bit beyond our usual comfort zone.
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![Clinical features and progression of Werner syndrome. Left photo panels are of Case 1, a Japanese-American WS patient reported by [@R20], at ages 15 (left) and 48 (right). Right photo panels are of a second Caucasian WS patient at ages \~13 (left) and 56 (right). Key clinical features of WS are present in both sets of photos, including the rounded face; sharp facial features; graying, thinning and loss of scalp and eyebrow hair; and in Patient 2 right panel thin, atrophic forearms and right elbow ulceration. Patient 1 archival photos, kindly provided by Drs. George Martin and Nancy Hanson of the International Registry of Werner Syndrome, were digitized and restored by Alden Hackmann. They are used courtesy of Lippincott Williams & Wilkins. Patient 2 photos were provided by Dr. George Martin, and are used here courtesy of the patient's spouse with informed consent of the patient, and of Elsevier Press where they were originally published in different form (Martin, GM (2005) Genetic modulation of senescent phenotypes in Homo sapiens. Cell 120:523--532).](nihms669182f1){#F1}
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Werner syndrome diagnostic criteria

  Category         WS signs and symptoms[\*](#TFN2){ref-type="table-fn"}
  ---------------- -----------------------------------------------------------
  *Cardinal*\*\*   1\. cataracts (bilateral)
                   2\. sclerodermalike skin changes
                   3\. short stature
                   4\. parental consanguinity
                   5\. premature greying and/or thinning of scalp hair
  *Additional*     1\. diabetes mellitus
                   2\. hypogonadism
                   3\. osteoporosis
                   4\. osteosclerosis (distal phalanges/fingers and/or toes)
                   5\. soft tissue calcification
                   6\. premature atherosclerosis
                   7\. neoplasia
                   8\. thin, highpitched voice

  Category          Diagnostic confidence   Diagnostic criteria
  ----------------- ----------------------- ---------------------------------------------------------------------------------------------------------
  *Definite*        *High confidence*       all cardinal signs + two additional signs ***OR*** confirmed pathogenic *WRN* mutations in both alleles
  *Probable*        *High confidence*       first 3 cardinal signs + any 2 others
  *Possible*        *Low confidence*        either cataracts or dermatological changes + any 4 additional signs
  *Exclusion*\*\*   *Exclude*               signs or symptoms before adolescence (except stature)

**notes:**

WS signs and symptoms are from the diagnostic criteria established by the International Registry of Werner Syndrome: [www.wernersyndrome.org/registry/diagnostic.html](http://www.wernersyndrome.org/registry/diagnostic.html), with additional discussion and application provided in [@R43].
